High-Grade Dysplasia — Advanced Precancerous Changes

Dysplasia describes atypical epithelial maturation and cellular architecture within a tissue. Pathologists grade dysplasia along a continuum—typically low-grade or high-grade—based on the degree of nuclear atypia, mitotic activity, and structural disorganisation. In high-grade dysplasia, cells exhibit prominent nuclear pleomorphism, hyperchromatism, high nuclear-to-cytoplasmic ratios, and abnormal mitotic figures throughout most of the epithelial thickness.

Crucially, high-grade dysplasia remains confined by the basement membrane. Because the abnormal cells have not penetrated this structural boundary, they have no access to vascular or lymphatic vessels and cannot metastasise. Clinically and histopathologically, high-grade dysplasia is often considered synonymous with carcinoma in situ.

Receiving a pathology report indicating high-grade dysplasia can be unsettling, but it represents a vital window of opportunity. Because the cells are still non-invasive, treating high-grade dysplasia can cure the abnormality completely before it ever gains the ability to spread into surrounding tissues or distant organs. Identifying and managing these lesions early protects patients from developing advanced malignancies that would require much more aggressive treatments like chemotherapy or radiation.

High-grade dysplasia cannot be felt or diagnosed by blood tests; it requires microscopic examination of tissue. Samples are gathered through screening or diagnostic procedures such as cervical Pap smears followed by colposcopy and biopsy, upper gastrointestinal endoscopy, or colonoscopy. A pathologist examines the fixed tissue slices using standard hematoxylin and eosin (H&E) staining, occasionally supplementing with immunohistochemical markers such as p53 or Ki-67 to confirm high cellular proliferation.

High-grade dysplasia is frequently identified in epithelial tissues monitored by routine cancer screening. It commonly occurs in the cervix (often designated cervical intraepithelial neoplasia grade 3, or CIN 3) as a consequence of persistent human papillomavirus (HPV) infection. It is also found in the esophagus arising within Barrett's esophagus, in the lining of the stomach, in colorectal adenomatous polyps, and within bladder urothelium.

Because high-grade dysplasia carries a significant risk of progression, standard management entails definitive local removal or ablation. Depending on the anatomic location, this may involve cervical loop electrosurgical excision procedures (LEEP) or cone biopsy, endoscopic mucosal resection (EMR), endoscopic submucosal dissection (ESD), or radiofrequency ablation (RFA). Following successful eradication, ongoing endoscopic or clinical surveillance is essential to watch for any recurrent dysplasia.